entertainment -WSS

entertainment

author：explore 2025-10-01 10:36:26 - browse：797

LONDON — AstraZeneca said on Monday that a new lung cancer treatment outperformed standard-of-care chemotherapy in a trial, but investors found the results less impressive than anticipated, sending company shares down in early trading.

Based on an interim analysis of a Phase 3 trial, the company said that the drug, datopotamab deruxtecan, led to improvement in progression-free survival in patients non-small cell lung cancer, a primary endpoint of the study. There was also a positive early trend on overall survival, with Susan Galbraith, AstraZeneca’s oncology leader, describing the results as “compelling evidence for the potential role” that the drug could play for patients.

But investors had been hoping for a clearer signal of benefit. Analysts noted that despite the success in progression-free survival, it was not described as a “clinically meaningful” improvement, which, as J.P. Morgan analysts wrote, “we believe the market would have liked to have seen.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： FDA approves first treatment for ultra

leisure time

WSS

Special counsel raises new conflict of interest concerns for De Oliveira's lawyer

Cancer drug shortages' outsize impact on ovarian cancer patients

A neonatal nurse in a British hospital has been found guilty of killing 7 babies

Trump's false claims about Georgia's 2020 election long debunked

ActiGraph execs on goal of drug approvals with digital endpoints

Tesla recalling nearly 16,000 of its 2021

hotspot

entertainment

explore

Malaria cases in Florida and Texas: Here’s what you need to know

Baltimore teen accused of firing into crowd during block party mass shooting

Supreme Court strikes down use of affirmative action

Indian pharmaceutical industry in denial over drug

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Affordable Connectivity Program vital to health care, experts say

Activists slam private health insurers over coverage restrictions

Ending racial health disparities hinges on penalties, political will

DIEP, the 'gold standard' of breast reconstruction, is under threat

Wife of Gilgo Beach murder suspect files for divorce, court filing shows

hotspot

Majority of Americans think Trump's Ga. election interference case is serious: POLL

Hospitals struggle to profit from CAR

Why Congress must ban federal programs from using QALYs

Ending racial health disparities hinges on penalties, political will

Listen: Racing for gene therapy & a pioneering approval

The boys, now 6, who are gene therapy’s ‘edge case’ problem

explore

leisure time

leisure time

focus